> Detailanzeige

Ackermann, Sandra; Cartolano, Maria; Hero, Barbara; Welte, Anne; Kahlert, Yvonne; Roderwieser, Andrea; Bartenhagen, Christoph; Walter, Esther; Gecht, Judith; Kerschke, Laura; Volland, Ruth; Menon, Roopika; Heuckmann, Johannes M.; Gartlgruber, Moritz; Hartlieb, Sabine; Henrich, Kai-Oliver; Okonechnikov, Konstantin; Altmüller, Janine; Nürnberg, Peter; Lefever, Steve; de Wilde, Bram; Sand, Frederik; Ikram, Fakhera; Rosswog, Carolina; [...]

A mechanistic classification of clinical phenotypes in neuroblastoma

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: A mechanistic classification of clinical phenotypes in neuroblastoma
  • Beteiligte: Ackermann, Sandra; Cartolano, Maria; Hero, Barbara; Welte, Anne; Kahlert, Yvonne; Roderwieser, Andrea; Bartenhagen, Christoph; Walter, Esther; Gecht, Judith; Kerschke, Laura; Volland, Ruth; Menon, Roopika; Heuckmann, Johannes M.; Gartlgruber, Moritz; Hartlieb, Sabine; Henrich, Kai-Oliver; Okonechnikov, Konstantin; Altmüller, Janine; Nürnberg, Peter; Lefever, Steve; de Wilde, Bram; Sand, Frederik; Ikram, Fakhera; Rosswog, Carolina; [...]
  • Erschienen: American Association for the Advancement of Science (AAAS), 2018
  • Erschienen in: Science
  • Sprache: Englisch
  • DOI: 10.1126/science.aat6768
  • ISSN: 1095-9203; 0036-8075
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>A systematic look at a childhood tumor</jats:title> <jats:p> Neuroblastomas—the most common tumor type in infants—develop from fetal nerve cells, and their clinical course is highly variable. Some neuroblastomas are fatal despite treatment, whereas others respond well to treatment and some undergo spontaneous regression without treatment. Ackermann <jats:italic>et al.</jats:italic> sequenced more than 400 pretreatment neuroblastomas and identified molecular features that characterize the three distinct clinical outcomes. Low-risk tumors lack telomere maintenance mechanisms, intermediate-risk tumors harbor telomere maintenance mechanisms, and high-risk tumors harbor telomere maintenance mechanisms in combination with RAS and/or p53 pathway mutations. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6419" page="1165" related-article-type="in-this-issue" vol="362" xlink:href="10.1126/science.aat6768">1165</jats:related-article> </jats:p>